Reportedly, prior to joining Endologix, Mr Abraham held several management positions at Edwards Lifesciences, including vice president, glucose monitoring, vice president, global supply chain and logistics and vice president of manufacturing.

Prior to joining Edwards, Mr Abraham was vice president and general manager of Sterilis, a development stage start-up focused on minimally invasive products for gynecology, urology and general surgery.

Mr Abraham began his career at Cordis (acquired by Johnson & Johnson in 1996), where he spent 14 years in positions of increasing responsibility, gaining operational and product development experience across several cardiovascular product categories and manufacturing lines.

Mr McDermott said: “Todd Abraham is a 25 year veteran of the medical device industry, with an impressive track record in manufacturing, operational management and commercialization. His experience is complemented by his endovascular product experience at Edwards Lifesciences and Cordis Corporation.

“He is an important addition to our management team as we execute on our strategy to expand our product portfolio to address the entire aortic stent graft market opportunity.”

Endologix develops and manufactures minimally invasive treatments for aortic disorders. The company’s product, Powerlink System, is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA).